Status:
COMPLETED
Addition of Ezetimibe (Ezetrol®) to Ongoing Therapy With Rosuvastatin (Crestor®) in HIV Positive Patients Not Reaching Cholesterol Targets
Lead Sponsor:
University of British Columbia
Collaborating Sponsors:
Merck Frosst-Schering Pharma, G.P.
Conditions:
Hypercholesterolemia
HIV Infections
Eligibility:
All Genders
19+ years
Phase:
NA
Brief Summary
This study involves comparing the effectiveness of treatments in HIV positive patients who may be predisposed to heart attack or stroke. The investigators will evaluate the effectiveness of two drugs,...
Detailed Description
This study seeks to determine whether HIV positive patients who have suboptimal lipids and/or are not reaching specified lipid targets will benefit from the addition of a second lipid lowering drug (e...
Eligibility Criteria
Inclusion
- HIV positive
- currently taking 10mg of rosuvastatin
- recent (within three months) fasting lipid profile in which the serum total cholesterol to HDL ratio is \>5.0
Exclusion
- Previous adverse reaction to ezetimibe
- taken ezetimibe within 30 days of starting the study
- history of vascular disease
- allergic reaction or muscle problems while taking any statin
- currently taking other lipid lowering medications (i.e. a fibrates or cholestyramine)
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2015
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT00908011
Start Date
June 1 2009
End Date
January 1 2015
Last Update
January 1 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Paul's Hospital HIV Immunodeficiency/Metabolic Clinic
Vancouver, British Columbia, Canada, V6Z 1Y6